Patents Assigned to Laboratorios S.A.L.V.A.T., S.A.
-
Patent number: 7115629Abstract: The invention relates to carbamates having general structure (I), wherein: R1, R2 and R3 are H, OH, SH, CN, F, Cl, Br, I, (C1–C4)-alkylthio, (C1–C4)-alkoxyl, (C1–C4)-alkoxyl substituted by one or several F radicals, carbamoylamine, (C1–C4)alkyl and (C1–C4)alkyl substituted by one or several F or OH radicals; R4 represents a substituted or non-substituted cycloalkyl or cycloaryl radical (a heteroalkyl radical or not). The amine of the quinuclidine ring can also be forming quaternary ammonium salts or in an oxidized state (N-oxide). Carbamates (I) are antagonists of the M3 muscarinic receptor, and selectively, the M2 receptor. Hence, they can be used in the treatment of urinary incontinence (particularly due to bladder instability), irritable bowel syndrome, diseases of the respiratory tract (particularly chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema and rhinitis) and in ophthalmologic operations.Type: GrantFiled: June 23, 2004Date of Patent: October 3, 2006Assignee: Laboratorios S.A.L.V.A.T., S.A.Inventors: Carles Farrerons Gallemi, Juan Lorenzo Catena Ruiz, Anna Fernandez Serrat, Ignacio José Miquel Bono, Dolors Balsa Lopez, José Ignacio Bonilla Navarro, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andrés Fernandez Garcia
-
Publication number: 20060189631Abstract: Compounds of general formula (I), wherein from A1 to A5, and from B1 to B5 are H, alkyl, alkoxyl, halogen, carboxylic derivatives or sulfur derivatives, among others; and from P1 to P3 are H, halogen, alkyl or alkoxyl, among others. Said compounds may be used for the chemoprevention and treatment of both precancerous lesions and cancer.Type: ApplicationFiled: January 27, 2006Publication date: August 24, 2006Applicant: LABORATORIOS S.A.L.V.A.T., S.A.Inventors: Juan Catena Ruiz, Carles Gallemi, Anna Serrat, Carmen Comas, Dolors Balsa Lopez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andres Fernandez Garcia
-
Publication number: 20060160894Abstract: Compounds of general structure (I), wherein the central benzene ring may be substituted in the meta- or para-position; -A is an optionally substituted hydroxyl, alkoxyl, hydroxylamine, alkoxylamine or amine radical; -W is an N- and C-linked biradical selected from several possibilities; and -Z is a carbon radical selected from several possibilities. These compounds are PPAR? and PPAR?/PPAR? modulators and, therefore, are useful for the prophylactic and/or curative treatment of a condition or a disease mediated by these recetpcors.Type: ApplicationFiled: June 11, 2004Publication date: July 20, 2006Applicant: LABORATORIOS S.A.L.V.A.T.,S.A.Inventors: Anna Fernandez Serrat, Carmen Serra Comas, Dolors Balsa Lopez, Amadeu Llebaria Soldevila, Carles Farrerons Gallemi, Ignacio Miquel Bono, Juan Catena, Carmen Lagunas Arnal, Arnau Cordomi Montoya, Carolina Salcedo Roca, Natividad Toledo Mesa, Pedro Marrero Gonzalez, Diego Haro Bautista, Andres Fernandez Garcia
-
Patent number: 6916828Abstract: The invention relates to carbamates having general structure (I), wherein: R1, R2 and R3 are H, OH, SH, CN, F, Cl, Br, I, (C1-C4)-alkylthio, (C1-C4)-alkoxyl, (C1-C4)-alkoxyl substituted by one or several F radicals, carbamoylamine, (C1-C4)-alkyl and (C1-C4)-alkyl substituted by one or several F or OH radicals; R4 represents a substituted or non-substituted cycloalkyl or cycloaryl radical (a heteroalkyl radical or not). The amine of the quinuclidine ring can also be forming quatemary ammonium salts or in an oxidized state (N-oxide). Carbamates (I) are antagonists of the M3 muscarinic receptor, and selectively, the M2 receptor. Hence, they can be used in the treatment of urinary incontinence (particularly due to bladder instability), irritable bowel syndrome, diseases of the respiratory tract (particularly chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema and rhinitis) and in ophthalmologic operations.Type: GrantFiled: June 25, 2001Date of Patent: July 12, 2005Assignee: Laboratorios S.A.L.V.A.T., S.A.Inventors: Carles Farrerons Gallemi, Juan Lorenzo Catena Ruiz, Anna Fernandez Serrat, Ignacio José Miquel Bono, Dolors Balsa Lopez, José Ignacio Bonilla Navarro, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andrés Fernandez Garcia
-
Publication number: 20040235887Abstract: The invention relates to carbamates having general structure (I), wherein: R1, R2 and R3 are H, OH, SH, CN, F, Cl, Br, I, (C1-C4)-alkylthio, (C1-C4)-alkoxyl, (C1-C4)-alkoxyl substituted by one or several F radicals, carbamoylamine, (C1-C4)alkyl and (C1-C4)alkyl substituted by one or several F or OH radicals; R4 represents a substituted or non-substituted cycloalkyl or cycloaryl radical (a heteroalkyl radical or not). The amine of the quinuclidine ring can also be forming quaternary ammonium salts or in an oxidized state (N-oxide). Carbamates (I) are antagonists of the M3 muscarinic receptor, and selectively, the M2 receptor. Hence, they can be used in the treatment of urinary incontinence (particularly due to bladder instability), irritable bowel syndrome, diseases of the respiratory tract (particularly chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema and rhinitis) and in ophthalmologic operations.Type: ApplicationFiled: June 23, 2004Publication date: November 25, 2004Applicant: LABORATORIOS S.A.L.V.A.T., S.A.Inventors: Carles Farrerons Gallemi, Juan Lorenzo Catena Ruiz, Anna Fernandez Serrat, Ignacio Jose Miguel Bono, Dolors Balsa Lopez, Jose Ignacio Bonilla Navarro, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andres Fernandez Garcia
-
Patent number: 6670365Abstract: The invention refers to new compounds of formula (I), wherein A and B are selected from the group consisting of N and CH, with the condition that when A is N, B is N; R1 is selected from the group consisting of CH3 and NH2; R2 and R3 are selected from the group consisting of H, CH3, Br, Cl, COCH3 and OCH3; and R4, R5 and R6, are selected from the group consisting of H, F, Cl, Br, (C1-C3)-alkyl, trifluoromethyl, (C1-C3)-alkoxy and trifluoromethoxy. Compounds of formula (I) are prepared by reaction of a substituted aminoazine with a substituted 2-bromo-2-(4-R1-sulfonylphenyl)-1-phenylethanone in a polar solvent. These new compounds inhibit COX-2 with high selectivity over COX-1. They are useful for the treatment of inflamation and/or cyclooxygenase-mediated diseases, having the additional advantage of a reduced potencial for ulcerogenic effects.Type: GrantFiled: April 5, 2001Date of Patent: December 30, 2003Assignee: Laboratorios S.A.L.V.A.T., S.A.Inventors: Carles Farrerons Gallemi, Ignacio-José Miquel Bono, Ana Maria Fernandez Serrat, Carlos Monserrat Vidal, Carmen Lagunas Arnal, Ferran Gimenez Guasch, Andrés Fernandez Garcia
-
Patent number: 5798348Abstract: The pharmaceutical and/or cosmetic compositions for treatment of obesity and/or overweight contain an effective amount of a fatty-acid monoester of an estrogen and a fatty acid wherein the estrogen is estrone, diethylstilbestrol, estriol, estradiol or ethinyl estradiol and the fatty acid is oleic, linoleic, linolenic, stearic, palmitic, palmitoleic or arachidonic acids. The fatty-acid monoesters mimic the function of estrone monooleate, as a signal that informs the brain of the size of fat tissue mass. In preferred pharmaceutical and/or cosmetic compositions for intravenous injection the monoester is incorporated in a lipidic suspension, prepared from lipoproteins or from liposome components, such as soy oil and egg phospholipids. When administered to rats with a 15% of total adipose tissue, they produce weight reduction of about 10%, by a new and unexpected mechanism. They are useful for the treatment of obesity and/or overweight in mammals, with the advantages of high efficacy and low toxicity.Type: GrantFiled: October 30, 1996Date of Patent: August 25, 1998Assignee: Laboratorios S.A.L.V.A.T., S.A.Inventor: Maria Alemany